Arecor Therapeutics (LON:AREC) Reaches New 1-Year Low – Time to Sell?

Arecor Therapeutics plc (LON:AREC)’s share price hit a new 52-week low on Thursday . The company traded as low as GBX 56 and last traded at GBX 57.50, with a volume of 73844 shares changing hands. The stock had previously closed at GBX 60.

Arecor Therapeutics Stock Down 4.2%

The company has a quick ratio of 6.24, a current ratio of 4.35 and a debt-to-equity ratio of 1.52. The stock has a market capitalization of £21.71 million, a P/E ratio of 28.75 and a beta of -0.18. The company has a fifty day moving average price of GBX 63.64 and a 200-day moving average price of GBX 68.68.

Arecor Therapeutics Company Profile

Arecor Therapeutics plc (AIM: AREC) is a clinical-stage biotech company developing superior therapeutics that can reduce treatment burden and improve outcomes for people living with diabetes, obesity and other cardiometabolic diseases.

Lead product, AT278, is the only ultra-concentrated (500U/mL) ultra-rapid-acting insulin in development. Arecor has signed an initial strategic partnership with Sequel Med Tech, a leading automated insulin delivery (AID) system company to co-develop AT278 in combination with Sequel’s twiist™ AID system.